Pharmacology & Pharmacy, 2013, 4, 490-495
http://dx.doi.org/10.4236/pp.2013.46071 Published Online September 2013 (http://www.scirp.org/journal/pp)
The Safety and Tolerance of Herbal Anti-Angina Drug
Compound Danshen Droplet Pill in Healthy Volunteers
Ying Zhou1, Yimin Cui1*, Xia Zhao1, Yong Huo2, Zhaohong Nie3,4, Min Zhao3,4, Z hixin Guo3,4, He Sun3,4
1Department of Pharmacy, Peking University First Hospital, Beijing, China; 2Department of Cardiology, Peking University First
Hospital, Beijing, China; 3Tasly Pharmaceutical Group Co., Ltd., Tianjin, China; 4Suntech Research Institutes, Rockville, USA.
Received June 19th, 2013; revised July 25th, 2013; accepted August 16th, 2013
Copyright © 2013 Ying Zhou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
Background: Compound Salvia Pellet (T89), consisting of Danshen (salvia miltiorrhiza), Sanqi (panax notoginseng),
and Borneol (Cinnamomum camphora), has been used worldwide for 14 years for chronic angina treatment. Purpose:
A dose escalation study to determine the maximum tolerance dose (MTD) in Chinese population to support a proposed
dose regimen change. Methods: Forty-six participants (age 18 to 45 yrs, male to female ratio = 1:1) were divided into a
series of 6 patients cohorts, and sequentially assigned into one of the escalating dose groups, starting from 540 mg, the
clinical doses, until 4 out of 6 subjects experience clinical Adverse Events (AEs) or when the pre-defined 3510 mg dose
level is reached and completed. All doses were given orally as a single dose 2 hours after breakfast. Adverse events,
vital signs, 12-lead ECG, clinical and laboratory parameters and medical evaluation were conducted as outcome meas-
ures. Results: Study completed at the highest pre-defined dose level of 3510 mg dose as never had 4/6 of subject ex-
perience AEs in any dose levels studied. All participants completed the study and data were included in the safety
analysis. The only moderate AE observation (muscle damage) was observed at 2970 mg dose and was recovered with-
out any medical treatment, and all other AEs (ECG, dizziness, muscle damage) were mild and may (5 cases) or may not
(9 cases) be related to testing drug and were all self-resolved within 30 min after dose. Conclusion: Given as single oral
dose, Compound Salvia Pellet is safe and well-tolerated up to the 3510 mg studied. The MTD value of Compound Sal-
via Pellet is unknown from this trial and must be higher than 3510 mg, 13 times higher than its current clinical dose.
Keywords: Compound Salvia Pellet; Safety; Tolerance; Chronic Angina Treatment
1. Introduction
Compound Salvia Pellet (T89), has been widely used in
China for 14 years, and used worldwide for more than 10
years. Compound Salvia Pellet is indicated for chronic
angina treatment [1,2], manufactured and marketed by
Tianjin Tasly Group Co., Ltd of P. R. China. T89 has
been marketed as composite Danshen pill [3], Compound
Danshen droplet pill [4], or Cadiotonic Pill, and Dantonic
Dripping pills. It is an herbal drug consisting of active
herbal ingredients co-extracted from Danshen (salvia
miltiorrhiza) and Sanqi (panax notoginseng), and tiny
amount of Borneol (Cinnamomum camphora) [3]. Ac-
cording to Traditional Chinese Medicine (TCM) concept,
salvia miltiorrhiza in this formula, which is regarded as
the principal drug (known as the “King drug”), can pro-
mote or invigorate blood flow and remove blood stasis.
Experimental studies have shown that salvia miltiorrhiza
can dilate coronary arteries, increase coronary blood flow
[5], and scavenge free radicals [6] in ischemic diseases,
so that it reduces the cellular damage from ischemia and
improves heart functions. Panax notoginseng serves as
“the Minister drug” to reinforce salvia miltiorrhiza’s
therapeutic action, which can inhibit activation of plate-
lets and their adhesion and aggregation [7], and counter-
act free-radical damage associated with atherogenesis
[8,9]. Cinnamomum camphora, for resuscitation, is re-
lated to the heart channel and lung channel, to “open and
revive the spirit” according to TCM. Clinical studies
demonstrated that T89 has numerous clinical effects on
increasing coronary flow rate and superoxide dismutase
activity, expanding the blood vessel, promoting blood
circulation, relieving blood stasis, improving the micro-
cycle and changing the blood viscidity, also decreasing
the consuming oxygen of the cardiac muscle, with the
*Corresponding author.

The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers 491
effects on anticancer, antibacterial, antiinflammation, etc.
[10-12].
A meta-analysis suggests that compound salvia pellet
is safe and does not develop tolerance over time [13].
However, most of the included trials were using lower
dose levels. Especially, the worldwide commonly used
clinical dosage of T89 is 270 mg each time, 3 times a day,
regardless of race, age, and body weight.
In 10 years of post-marketing safety watch, Composite
Salvia Dropping Pill showed none severe adverse reac-
tion. Meanwhile, clinicians frequently use higher dose in
clinical practice. Based on preclinical studies sponsored
by Tasly Pharmaceutical Group, the LD50 in mice after
single dose is 16.7 mg/kg (Is it 16.7 mg or 16.7 mg/kg?
Is the number correct?). The result of long term toxicity
test indicates that the highest dosage among the three
testing groups used in this animal study is the 50 times
higher than human common dose.
The objective of this dose escalation study was to es-
timate the MTD in Chinese population to support a pro-
posed dose regimen change.
2. Materials and Methods
2.1. Study Drug Administration
Clinical trial material (CTM) was a two herbal mixture
extract preparation and was produced and provided by
Tianjin Tasly Group Co., Ltd. CTM for the phase I type
MTD study was supplied as 27-mg pills. The Batch
Number was 20060908.
2.2. Study Design
This randomized, open label, dose escalation study of
Composite Salvia Dropping Pill was performed in Chi-
nese healthy volunteers. A total of 46 healthy, nonsmok-
ing volunteers, 18 to 45 years of age (difference is not fit
to be 10 years in the same group (I cannot understand
this sentence, please revise)) and with body mass index
(BMI) between 19.0 and 25.0 kg/m2. All participants
were able to give written informed consent before to be
enrolled in the study, same numbers of male and female
subjects were enrolled to ensure gender balance. The
study was conducted in according with Good Clinical
Practice and International Council on Harmonization
guidelines. The study protocols and the informed consent
were approved by the Clinical Drug Trial Ethical Com-
mittee of the Peking University First hospital. Study
personnel obtained written informed consent directly
from all subjects prior to their entry into the study.
The nine single doses of T89 evaluated were 20, 40,
60, 70, 80, 90, 100, 120, and 130 pills of the 27 mg for-
mulation. The doses were administered orally with 500
mL warm water 2 hours before meal. All subjects were
randomly divided into 9 groups, 6 subjects per group.
Volunteers were admitted to the study unit the day before
each scheduled dosing period and remained at the study
site for 24 hours after dosing. Does escalation were
started from the lowest dose, and move to the next dose
until all safety profile were checked and observed. Each
subject only toke one dose and was not repeated for any
other dose level. The stopping criteria for dose escalation
was that if testing drug related adverse reaction were
observed in 4/6 subjects, the same dose will be repeated.
If the same or higher frequency of adverse reaction was
observed again, MTD will be defined as the dose that is
one level lower. If adverse reaction rate was lower than
4/6 in the repeated dose level, dose escalation will con-
tinue to move to a higher dose. All dose groups were
monitored on a combined inpatient/outpatient basis.
During the one week outpatient period, subjects reported
daily to the study unite for scheduled events and proce-
dures.
2.3. Safety and Tolerability Evaluations
The tolerability and safety of T89 were evaluated based
on adverse-event reports, vital signs, electrocardiograms,
clinical laboratory values, and results of physical exami-
nation. Study subjects were monitored carefully through-
out each dosing period for adverse experiences. The rela-
tionship of adverse events to the study drug was assessed
by a qualified physician and is in general based on such
considerations as temporal relationship to study drug
administration, subject’s relevant medical history, and
whether the finding is likely due to any pre-existing con-
ditions.
Electrocardiograms monitoring was performed using
Twelve-lead ECG (PHILIPS Page Writer Trim III, USA
Philips Co. Ltd.). The measurements were made at the
first screening visit, pre-administration, 0.5, 1, 2, 3, 4, 6,
8, 24 h and 7 d after test drug administration and any
other time if necessary. Except for adverse events,
12-lead ECG, vital signs and clinical laboratory, includ-
ing CK, CK-MB, HBDH, CTN I were evaluated.
2.4. Statistics
A paired t test was used to evaluate the safety data within
each group (within each group or for each subject?), and
P-values of less than 0.05 were considered as statistically
significant.
3. Results
3.1. Enrollment and Demographics
A total of 46 Chinese male or female healthy subjects
were enrolled in the study with the age of 26 to 39 years,
22 males and 24 females. Subjects for these study were
similar in age (35.1 ± 3.43 years); weight (60.0 ± 8.25

The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers 492
kg); height (1.62 ± 0.079 m); and body mass index (22.8
± 1.92) (Table 1).
As shown in Table 1, 9 of the subjects were current
smokers. All smoking subjects were aged between 20
and 25, except for subject 120 who was 19 upon screen-
ing. This subject was discontinued from the study upon
discovery of that he started smoking was outside the age
range for inclusion criterion. The average height of all
subjects was 171 cm (range: 163 - 183 cm), with an av-
erage weight of 65.3 kg (range: 53.0 - 82.0 kg). The BMI
ranged between 19.2 - 27.0 kg/m2 with a mean of 22.4
kg/m2.
3.2. Safety Observations
Safety was monitored at 0.5, 1, 2, 3, 4, 6, 8, 24 h and 7
days postdose. Adverse events (ADR) in all dose levels
were recorded. All participants completed the study and
were included in the safety data analysis. Any clinically
significant change in laboratory values post drug admini-
stration compared to baseline were recorded as ADR and
are summarized in Table 2.
Overall, during the course of the study, there was no
significant change in vital signs when compared to pre-
dose baseline. Specifically, thirteen out of 46 subjects
reported a total of 14 treatment-emergent mild or moder-
ate adverse events (all causalities) during the study. Five
out of the 14 events were judged by the investigator to be
related to study drug, while the other 9 were considered
unrelated. All of the reported adverse events were mild
except for that the muscle damage was rated as moderate.
All the adverse events disappeared spontaneously.
There were no clinically significant ECG findings re-
ported except one case of ST-T change. (Please provide a
little more information, such as what types of change,
degree, recovery and etc.).
There were also no clinically significant alterations in
laboratory values except one subject showed a single lift
of ALT, HBDH, CK, CK-MB, TBIL, TG, WBC, LEU
values after the 120 pills dose level. This subject’s CK,
CK-MB and MB have significant clinical differences 2
days after drug administration. The subject was in-
structed to take a lot of water after the diagnosis. All the
laboratory values were improved 5 days afterwards.
Double check on day 11 showed everything are back to
normal. Table 3 summarizes CK, CK-MB, MB and other
laboratory values for baseline, day 1 and day 7 for this
subject. It can be seen that the CK levels increased after
both day 1 and day 7 post dose comparing baseline.
However, they were still within the normal range and
was not clinically significant alterations.
3.3. MTD Value
Although 120 × 27 mg dose group had one subject ex-
perienced muscle injury with moderate degree, this does
not warrantee to stop the trial. Next dose of 130 × 27 mg
dose was continued with caution. Neither ADRs, nor CK
ascending symptoms were observed in the 130 pills
group.
According to pre-defined study protocol, if in the ac-
celerative process, more than 4/6 of the subjects indicate
severe adverse reaction directly related to the trial drugs,
the acceleration must be stopped and repeated. The trial
reached its final termination dose level at 130 pills with-
out any clinical severe adverse reaction. Therefore, the
MTD should be greater than 130 pills.
4. Discussion
Chronic stable angina is a major health problem that af-
fects over 7 million adults in the United States, with an
estimated 400,000 new cases annually [14], and it results
in a considerable burden for both the individual and
Table 1. Subjects studied.
T89
20 × 27 mg
group
40 × 27 mg
group
60 × 27 mg
group
70 × 27 mg
group
80 × 27 mg
group
90 × 27 mg
group
100 × 27 mg
group
120 × 27 mg
group
130 × 27 mg
group
Total subjects 4 4 4 4 6 6 6 6 6
Male 2 2 2 2 3 3 2 4 2
Female 2 2 2 2 3 3 4 2 4
Age (years)
Mean 30.8 37.8 34.8 35.3 35.7 33.8 37.3 34.7 36.8
Range 30 - 32 37 - 38 31 - 38 32 - 38 31 - 38 31 - 39 37 - 38 30 - 39 26 - 39
BMI (kg/m2)
Mean 22.8 23.7 22.9 22.3 22.3 22.2 22.9 23.5 23.1
Range 20.7 - 24.7 21.7 - 25.0 21.0 - 25.021.2 - 23.619.5 - 24.419.2 - 24.919.5 - 25.0 20.1 - 25.0 19.5 - 25.0
Race
Asian 4 4 4 4 6 6 6 6 6

The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers 493
Table 2. Frequency of treatment-emergent drug-related* adverse events by type.
Number of adverse events
[number of subjects with adverse event]
MedDRA term 20 × 27 mg
group
(N = 4)
40 × 27 mg
group
(N = 4)
60 × 27 mg
group
(N = 4)
70 × 27 mg
group
(N = 4)
80 × 27 mg
group
(N = 6)
90 × 27 mg
group
(N = 6)
100 × 27 mg
group
(N = 6)
120 × 27 mg
group
(N = 6)
130 × 27 mg
group
(N = 6)
Vascular disorders
abnormal ECG 1 [1]
Nervous system disorders
Dizziness 1 [1] 1 [1]
Dizziness and sweat 1 [1]
Musculoskeletal and
connective tissue disorders
muscle damage 1 [1]
Total 1 [1] 1 [1] 1 [1] 2 [2]
N = Number of subjects; *Adverse events with possible or probable relationship to study drug.
Table 3. Level of clinical laboratory by subjects in 130 × 27 mg group.
Special
laboratory (unites) Reference range Baseline Change from baseline to1d 1 d Change from baseline to 7 d 7 d
PT (s) 10 - 14 10.5 ± 0.4 −0.6 ± 0.5* 9.9 ± 0.4 −0.2 ± 0.1 10.3 ± 0.4*
APTT (s) 23 - 35 26.3 ± 0.9 0.1 ± 2.2 26.4 ± 1.9 0.8 ± 2.0 27.1 ± 1.8
AST (U/L) 0 - 45 25.3 ± 3.4 −2.5 ± 4.5 22.8 ± 4.2 −6.1 ± 5.6 19.2 ± 2.3*
ALT (U/L) 0 - 40 14.6 ± 5.8 1.6 ± 7.2 16.2 ± 8.6 0.5 ± 9.8 15.1 ± 6.4
CREA (μmol/L) 35 - 97 51.1 ± 11.6 11 ± 14.6* 62.1 ± 13.5 1.1 ± 14.2 52.2 ± 7.8
BUN (μmol/L) 2.9 - 7.2 3.9 ± 0.3 0.5 ± 0.5 4.4 ± 0.7 0.3 ± 1.7 4.2 ± 1.1
GLu (mmol/L) 3.31 - 6.1 5.8 ± 0.9 −0.8 ± 1.0* 5.0 ± 0.2 −0.5 ± 1.2 5.3 ± 0.8
TCHO (mmol/L) 3.1 - 5.66 4.86 ± 0.58 −0.23 ± 0.34 4.63 ± 0.67 −0.57 ± 0.66 4.29 ± 0.64*
TG (mmol/L) 0.14 - 1.8 0.9 ± 0.47 0.58 ± 0.86* 1.48 ± 0.74 0.04 ± 0.82 0.94 ± 0.56
HDL-C (mmol/L) 1.00 - 1.55 1.39 ± 0.18 −0.14 ± 0.25 1.25 ± 0.16 −0.13 ± 0.12 1.26 ± 0.08
LDL-C (mmol/L) 2.1 - 3.1 2.9 ± 0.39 −0.22 ± 0.56 2.68 ± 0.47 −0.37 ± 0.66 2.53 ± 0.42*
MB (ng/ml) <100 18.75 ± 4.08−1.32 ± 3.64 17.43 ± 1.58 −3.2 ± 2.89 15.55 ± 3.53
CK (U/L) 24 - 170 123.9 ± 25.6−49.5 ± 19.2* 74.4 ± 17.4 −25.7 ± 22.9 98.2 ± 17.3*
CK-MB (U/L) 2 - 25 9.5 ± 8.0 −4.1 ± 6.4 5.4 ± 4.2 −3.0 ± 5.4 6.5 ± 4.4
Baseline, change (baseline to 1 d, baseline to 7 d), and 1 d, 7 d, means ± SD, for levels of clinical laboratory by Subjects in 130 × 27 mg Group, the maximum
tolerated dose (MTD) group are shown. *p < 0.05, within groups. There were statistically significant differences not clinically significant alterations, still in the
normal range.
society. At present, organic nitrates are indicated as the
firstline therapy for the long-term management of chro-
nic stable angina [15-18]. Organic nitrates have been
prescribed to patients with stable angina in the last 100
years or more and are still widely used in the treatment of
such patients. However, some adverse effects have also
been reported. The major problem with long-term used of
nitroglycerin and long-acting nitrates is development of
tolerance. Although in some clinical trials intermittent
therapy seems to be a hopeful strategy in preventing ni-
trate tolerance and has proved superior to continuous
therapy [19,20], it still has problems, such as possible
association with rebound myocardial ischemia during the
nitrate-free period and adverse effects on performance on
treadmill exercise tests during the period of withdrawal
from nitrates [16]. In search of better treatment options,
many patients in both east and west have turned to alter-
native medicines in the hopes of identifying “natural”
substances with less toxicity but equal effectiveness. T89,
as one of the alternative therapies, is widely used in
China and worldwide, as drug or dietary supplement, but
the best clinical dose to ensure the efficacy and safety of
T89 for the treatment of chronic stable angina pectoris
needs further investigation. Until now, many randomized
controlled trials (RCTs) have been completed or pub-
lished which indicate that T89 may be effective in

The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers 494
patients with chronic stable angina pectoris compared
with the organic nitrates [21]. But most of the included
trials were at lower doses or inclusive [13]. This study
demonstrated that T89 was well tolerated after admini-
stration as a single oral dose across the 20 × 27 mg to
130 × 27 mg dose range. Moreover, rigorously designed,
multi-center, large, randomized, double-blind, controlled
trial is being performed in the USA.
In a retrospective meta-analysis, adverse events were
described in 17 of the 27 trials (63.0%). Adverse events
were reported in 26 of 1093 (2.4%) patients treated with
CSP [13]. Abdominal complaints, nausea, dyspepsia and
dizziness were reported most often, and which com-
pletely alleviated without any treatment [13,21,22]. Diz-
ziness was the most adverse events that have been re-
ported, and duration prolonged as the dosage ascends. In
this trial, the 40 × 27 mg group, 70 × 27 mg group, and
120 × 27 mg group each had one case of adverse event,
and the attacking time was about 1 hour to 2 hours after
administration with duration of 3 minutes, 7 minutes or
20 hours, accompanied with deficient sweating. It seems
the degree of sweating is related to dose. All the three
subjects were female, who might be more sensitive to the
drugs. The first and only moderate AE (muscle damage)
was observed at 120 × 27 mg dose and were recovered
without medical treatment. None CK ascending symp-
toms occurred in the following 130 × 27 mg group. How-
ever, such observation suggests muscle damage could be
observed and should be monitored in case of overdose.
The mechanism of muscle damage is waiting to be inves-
tigated.
Clinical Tolerance Study usually are conducted before
large clinical phase 2 or phase 3 trials. Mice LD50 of sin-
gle dose was 16.7 mg/kg. Long term toxicity study indi-
cates that highest dose is 50 times higher than human
dose. At single oral dose, T89 is safe and well-tolerated
up to 130 × 27 mg dose. The MTD value of T89 in this
study was not reached, is unknown, and must be higher
than 130 × 27 mg.
5. Conclusion
In conclusion, T89 was well tolerated after administra-
tion as a single dose to across the 20 × 27 mg to 130 × 27
mg dose rage. T89 was safe and well tolerated at the
highest dose level studies: 130 × 27 mg. The MTD value
of T89 was not reached in this trial, which was unknown,
and must be higher than 130 × 27 mg.
REFERENCES
[1] C.-E. Deng, “Progress on Pharmacological and Clinical
Application of Salvia Miltiorrhiza,” Lishizhen Medicine
and Materia Medica Research, Vol. 14, No. 12, 2003, p.
776.
[2] N. Ding, “Research Advancement and Clinical Applica-
tion of Compound Danshen,” Chinese Traditional and
Herbal Drugs, Vol. 33, No. 12, 2002, pp. 1147-1148. (in
Chinese)
[3] Z. X. Guo, W. Jia, W. Y. Gao, et al., “Clinical Investiga-
tion of Composite Danshen Pill for the Treatment of An-
gina Pectoris,” Chinese Journal of Natural Medicines,
Vol. 1, No. 2, 2003, pp. 124-128. (in Chinese)
[4] Y. H. Shi, “Comparative Study of Composite Danshen
Droplet Pills and Sordid in Treatment of Patients with
Chronic Stable Angina,” Zhongguo Zhong Xi Yi Jie He
Za Zhi, Vol. 17, No. 1, 1997, pp. 23-25. (in Chinese)
[5] W. Zhou and T. J. Ruigrok, “Protective Effect of Danshen
during Myocardial Ischemia and Reperfusion: An Isolated
Rat Heart Study,” The American Journal of Chinese
Medicine, Vol. 18, No. 1, 1990, pp. 19-24.
doi:10.1142/S0192415X90000046
[6] A. M. Wang, S. H. Sha, W. Lesniak, et al., “Tanshinone
(Salviae miltiorrhizae Extract) Preparations Attenuate
Aminoglycoside-Induced Free Radical Formation: In Vi-
tro and Ototoxicity in Vivo,” Antimicrobial Agents and
Chemotherapy, Vol. 47, No. 6, 2003, pp. 1836-1841.
doi:10.1128/AAC.47.6.1836-1841.2003
[7] J. Wang, J. Xu, J. B. Zhong, et al., “Effect of Radix
Notoginseng Saponins on Platelet Activating Molecule
Expression and Aggregation in Patients with Blood Hy-
perviscosity Syndrome,” Zhongguo Zhong Xi Yi Jie He
Za Zhi, Vol. 24, No. 4, 2004, pp. 312-316. (in Chinese)
[8] P. Chan, G. N. Thomas and B. Tomlinson, “Protective
Effects of Trilinolein Extracted from Panax Notoginseng
against Cardiovascular Disease,” Acta Pharmacologica
Sinica, Vol. 23, No. 12, 2002, pp. 1157-1162.
[9] W. Zhou, H. Chai, P. H. Lin, et al., “Molecular Mecha-
nisms and Clinical Applications of Ginseng Root for Car-
diovascular Disease,” Medical Science Monitor, Vol. 10,
No. 8, 2004, pp. RA187-RA192.
[10] Y.-J. Wu, C.-Y. Hong, S.-J. Lin, P. Wu and M.-S. Shiao,
“Increase of Vitamin E Content in LDL and Reduction of
Atherosclerosis in Cholesterol-Fed Rabbits by a Water-
Soluble Antioxidant-Rich Fraction of Salvia miltior-
rhiza,” Thrombosis, and Vascular Biology, Vol. 18, 1998,
pp. 481-486. doi:10.1161/01.ATV.18.3.481
[11] O. Karmin, E. G. Lynn, R. Vazhappilly, K. K. W. Au-
Yeung, D.-Y. Zhu and Y. L. Siow, “Magnesium Tanshi-
noate B (MTB) Inhibits Low Density Lipoprotein Oxida-
tion,” Life Sci ences, Vol. 68, No. 8, 2001, pp. 903-912.
doi:10.1016/S0024-3205(00)00989-9
[12] T. Kyoko, O. Xinshou, K. Katsuko, N. Norio, H. Masao
and B. Akemichi, “Sodium Tanshinone IIA Sulfonate
Derived from Danshen (Salvia miltiorrhiza) Attenuates
Hypertrophy Induced by Angiotensin II in Cultured Neo-
natal Rat Cardiac Cells,” Biochemical Pharmacology, Vol.
64, No. 4, 2002, pp. 745-750.
doi:10.1016/S0006-2952(02)01250-9
[13] G. Wang, L. Wang, Z. Y. Xiong, B. Mao and T. Q. Li,
“Compound Salvia Pellet, a Traditional Chinese Medicine,
for the Treatment of Chronic Stable Angina Pectoris
Compared with Nitrates: A Meta-Analysis,” Medical
Science Monitor, Vol. 12, No. 1, 2006, pp. SR1-SR7.

The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers 495
[14] P. Mickie, R. Peled, L. Matityhau, et al., “Reasons for
Overprescription of Mononitrates: The Paradigm of Sta-
ble Angina Pectoris Treatment,” Current Therapeutic
Research, Vol. 64, No. 9, 2003, pp. 662-675.
doi:10.1016/j.curtheres.2003.09.013
[15] S. P. Glasser, “Clinical Mechanisms of Nitrate Action,”
American Journal of Cardiology, Vol. 81, No. 1, 1998, pp.
49A-53A. doi:10.1016/S0002-9149(97)00998-3
[16] S. D. Fihn, S. V. Williams, J. Daley, et al., “American
College of Cardiology, American Heart Association,
American College of Physicians-American Society of In-
ternal Medicine Guidelines for the Management of Pa-
tients with Chronic Stable Angina: Treatment,” Annals of
Internal Medicine, Vol. 135, No. 8, 2001, pp. 616-632.
doi:10.7326/0003-4819-135-8_Part_1-200110160-00014
[17] M. Eccles, “North of England Stable Angina Guideline
Development Group: North of England Evidence Based
Guidelines Development Project: Summary Version of
Evidence Based Guideline for the Primary Care Man-
agement of Angina,” BMJ, Vol. 312, 1996, pp. 827-832.
doi:10.1136/bmj.312.7034.827
[18] R. J. Gibbons, J. Abrams, K. Chatterjee, et al., “ACC/
AHA 2002 Guideline Update for the Management of Pa-
tients with Chronic Stable Angina—Summary Article: A
Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines
(Committee on the Management of Patients with Chronic
Stable Angina),” Circulation, Vol. 107, 2003, pp. 149-
158. doi:10.1161/01.CIR.0000047041.66447.29
[19] S. Silber, “Nitrates: Why and How Should They Be Used
Today?” European Journal of Clinical Pharmacology,
Vol. 3, No. 1, 1990, pp. S35-S51.
doi:10.1007/BF01417564
[20] P. A. Todd, K. L. Goa and H. D. Langtry, “Transdermal
Nitroglycerin (Glyceryl Trinitrate): A Review of Its
Pharmacology and Therapeutic Use,” Drugs, Vol. 40, No.
6, 1990, pp. 880-902.
doi:10.2165/00003495-199040060-00009
[21] S. Y. Zai, R. Chen and X. H. Wu, “Clinical Observation
on Compound Salvia Pellet in the Treatment of 41 Cases’
Migraine,” Journal of Practical, Traditional Chinese Me-
dicine, Vol. 22, No. 1, 2006, p. 26.
[22] G. Y. Hu and F. H. Cai, “Clinical Observation of Curative
Effect of Compound Danshen Pellet in Unstable Angina,”
Chinese Journal of Cardiovascular Review, Vol. 1, No. 1,
2003, pp. 38-40.